IL128718A0 - Naaldase compositions - Google Patents

Naaldase compositions

Info

Publication number
IL128718A0
IL128718A0 IL12871897A IL12871897A IL128718A0 IL 128718 A0 IL128718 A0 IL 128718A0 IL 12871897 A IL12871897 A IL 12871897A IL 12871897 A IL12871897 A IL 12871897A IL 128718 A0 IL128718 A0 IL 128718A0
Authority
IL
Israel
Prior art keywords
naaldase
compositions
naaldase compositions
Prior art date
Application number
IL12871897A
Other languages
English (en)
Original Assignee
Guildford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/718,703 external-priority patent/US5824662A/en
Priority claimed from US08/842,360 external-priority patent/US6054444A/en
Priority claimed from US08/858,985 external-priority patent/US6025344A/en
Priority claimed from US08/863,624 external-priority patent/US6046180A/en
Priority claimed from US08/884,479 external-priority patent/US6017903A/en
Application filed by Guildford Pharmaceuticals Inc filed Critical Guildford Pharmaceuticals Inc
Publication of IL128718A0 publication Critical patent/IL128718A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4465—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12871897A 1996-09-27 1997-08-15 Naaldase compositions IL128718A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/718,703 US5824662A (en) 1996-09-27 1996-09-27 Treatment of global and focal ischemia using naaladase inhibitors
US08/842,360 US6054444A (en) 1997-04-24 1997-04-24 Phosphonic acid derivatives
US08/858,985 US6025344A (en) 1996-06-17 1997-05-27 Certain dioic acid derivatives useful as NAALADase inhibitors
US08/863,624 US6046180A (en) 1996-06-17 1997-05-27 NAALADase inhibitors
US08/884,479 US6017903A (en) 1996-09-27 1997-06-27 Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
PCT/US1997/014344 WO1998013046A1 (en) 1996-09-27 1997-08-15 Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals

Publications (1)

Publication Number Publication Date
IL128718A0 true IL128718A0 (en) 2000-01-31

Family

ID=27542138

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12871897A IL128718A0 (en) 1996-09-27 1997-08-15 Naaldase compositions

Country Status (16)

Country Link
US (1) US6413948B1 (cg-RX-API-DMAC10.html)
EP (1) EP1005348A1 (cg-RX-API-DMAC10.html)
JP (1) JP2002514184A (cg-RX-API-DMAC10.html)
KR (1) KR20000036227A (cg-RX-API-DMAC10.html)
CN (1) CN1230889A (cg-RX-API-DMAC10.html)
AU (1) AU733880B2 (cg-RX-API-DMAC10.html)
CA (1) CA2264043A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ60499A3 (cg-RX-API-DMAC10.html)
HU (1) HUP0001062A3 (cg-RX-API-DMAC10.html)
IL (1) IL128718A0 (cg-RX-API-DMAC10.html)
LV (1) LV12283A (cg-RX-API-DMAC10.html)
NO (1) NO991387L (cg-RX-API-DMAC10.html)
NZ (1) NZ334780A (cg-RX-API-DMAC10.html)
PL (1) PL332413A1 (cg-RX-API-DMAC10.html)
TR (1) TR199901173T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998013046A1 (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7070782B1 (en) * 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
WO1996026272A1 (en) 1995-02-24 1996-08-29 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
ID20347A (id) * 1997-05-27 1998-12-03 Guilford Pharm Inc Inhibitor aktifitas enzim naaladase
WO1999008521A1 (en) * 1997-08-14 1999-02-25 Department Of The Army, U.S. Government Treatment or prophylaxis of retinal pathology and spinal cord injury
AU3822902A (en) * 1997-08-18 2002-06-27 Queen's University At Kingston Phosphono-carboxylate compounds for treating amyloidosis
NZ550116A (en) * 1997-08-18 2008-03-28 Neurochem Int Ltd Phosphono-carboxylate compounds for treating amyloidosis
US6329356B1 (en) 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
JP5095050B2 (ja) 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、NAALADaseの阻害剤
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6228888B1 (en) * 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
WO2001012171A2 (en) * 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
US20020013295A1 (en) * 2000-05-30 2002-01-31 Slusher Barbara S. Naaladase inhibitors for treating amyotrophic lateral sclerosis
AU2001265111A1 (en) * 2000-05-30 2001-12-11 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
CA2436408A1 (en) 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US7148250B2 (en) * 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
DE602004021476D1 (de) * 2003-03-03 2009-07-23 Eisai Corp North America THIOLACTONE ALS NAALADase INHIBITOREN
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2005305609B2 (en) 2004-09-17 2011-10-06 Idenix Pharmaceuticals, Inc. Phosphoindoles as HIV inhibitors
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
ES2684322T3 (es) 2006-11-08 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
WO2012082903A2 (en) * 2010-12-14 2012-06-21 The Johns Hopkins University Treatment of cognitive impairment in a subject with a neurological autoimmune disease
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
HUE035739T2 (en) 2013-01-14 2018-05-28 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radiological imaging agents

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5162512A (en) 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US5093525A (en) 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4906779A (en) 1986-07-10 1990-03-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5190976A (en) 1986-07-10 1993-03-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
JP2608550B2 (ja) * 1986-10-17 1997-05-07 株式会社 片山化学工業研究所 軟水ボイラの防食処理方法
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4918064A (en) 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
US5871472A (en) 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
DE3854991T2 (de) 1987-11-27 1996-07-18 Eisai Co Ltd Cyclische Amine und pharmakologische Verbindungen
US5196439A (en) 1987-11-27 1993-03-23 Eisai Co., Ltd. Piperidine compounds useful to treat cerebrovascular diseases
US4937183A (en) 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5047227A (en) 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
US5177109A (en) 1988-05-16 1993-01-05 G. D. Searle & Co. 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders
IT1217603B (it) 1988-05-16 1990-03-30 Uni Degli Studi Perugia Derivati di acido 2 ammino 4,5 metilen adipico attivi sul sistema nervoso centrale
DE68912822T2 (de) 1988-05-16 1994-06-09 Searle & Co 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen.
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
FI93838C (fi) 1988-06-28 1995-06-12 Novo Nordisk As Menetelmä uusien terapeuttisesti käyttökelpoisten 7,8-dihydroksi-1H-imidatso- ja pyratsolo/3,4-f/kinoksaliinijohdannaisten valmistamiseksi
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
DE3839659A1 (de) 1988-11-24 1990-05-31 Boehringer Ingelheim Kg Verwendung von benzomorphanen zur zytoprotektion
FR2649701B2 (fr) 1988-12-15 1991-11-22 Rhone Poulenc Sante Derives d'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2640624B1 (fr) 1988-12-15 1994-08-12 Rhone Poulenc Sante Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
ES2043070T3 (es) 1988-12-15 1993-12-16 Rhone Poulenc Sante Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
ES2052954T3 (es) 1988-12-15 1994-07-16 Rhone Poulenc Sante Derivados de imino-2-polifluoroalcoxi-6-benzotiazol, sus procedimientos de preparacion y los medicamentos que les contienen.
FR2640622B1 (fr) 1988-12-15 1991-03-22 Rhone Poulenc Sante Derives de l'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2649705B2 (fr) 1989-07-13 1994-09-23 Rhone Poulenc Sante Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
FR2649703B1 (fr) 1989-07-13 1991-11-22 Rhone Poulenc Sante Derives d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procedes de preparation et les medicaments les contenant
US5196510A (en) 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US4994446A (en) 1989-01-03 1991-02-19 Ramot - University Authority For Applied Research And Industrial Development Ltd. Drug system
US5011834A (en) 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
FR2649702B1 (fr) 1989-07-13 1991-11-22 Rhone Poulenc Sante Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
CA2069912A1 (en) 1989-10-25 1991-04-26 The Regents Of The University Of California Method of inhibiting the transport of l-glutamate
US5521215A (en) 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5284867A (en) 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
IL92238A (en) 1989-11-07 1995-07-31 Yissum Res Dev Co ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
IT1238346B (it) 1989-11-14 1993-07-13 Gangliosidi modificati e loro derivati funzionali.
FR2662160B1 (fr) 1990-05-18 1992-07-24 Rhone Poulenc Sante Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
US5130330A (en) 1990-01-31 1992-07-14 G. D. Searle & Co. Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for cns disorders
US5262568A (en) 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
IE910719A1 (en) 1990-03-02 1991-09-11 Oregon State Tri- and tetra-substituted guanidines and their use as¹excitatory amino acid and antagonists
US5336689A (en) 1990-03-02 1994-08-09 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
FR2662694A1 (fr) 1990-06-05 1991-12-06 Rhone Poulenc Sante Derives du benzoselenazole, leur preparation et les medicaments les contenant.
FR2662695A1 (fr) 1990-06-05 1991-12-06 Rhone Poulenc Sante Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant.
FR2663029B1 (fr) 1990-06-07 1992-07-31 Rhone Poulenc Sante Derives de benzothiazole, leur preparation et les medicaments les contenant.
JPH0474197A (ja) 1990-07-12 1992-03-09 Naoyoshi Suzuki 新規な免疫調整生理活性ペプチド
US5089517A (en) 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5145862A (en) 1990-08-16 1992-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
WO1992004023A1 (en) 1990-09-10 1992-03-19 Shug Austin L Composition and method for protecting the heart during reperfusion
US5158976A (en) 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
EP0940139B1 (en) 1991-02-08 2005-02-02 Scion Pharmaceuticals, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5135080A (en) 1991-04-30 1992-08-04 E. I. Du Pont De Nemours And Company Stand up fork lift truck safety net
JP2632754B2 (ja) 1991-05-21 1997-07-23 塩野義製薬株式会社 脳内グルタミン酸遊離抑制剤
FR2678619B1 (fr) 1991-07-04 1993-09-17 Rhone Poulenc Rorer Sa Derives de 1,2,4-thiadiazolo[3,4-b]benzothiazole, leur preparation et les medicaments les contenant.
US5502166A (en) 1992-02-26 1996-03-26 Mitsubishi Chemical Corporation NMDH receptor proteins and genes encoding the same
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
DE4212529A1 (de) 1992-04-10 1993-10-14 Schering Ag Verwendung von µ-Carbolinen als nicht-kompetitive Glutamat-Antagonisten
USH1312H (en) 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
WO1993025203A1 (en) 1992-06-17 1993-12-23 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo[a,d]cyclohepten-5,10-imine
IT1260156B (it) 1992-08-03 1996-03-28 Fidia Spa Derivati dell'acido neuraminico
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP1757695A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5319095A (en) 1992-12-04 1994-06-07 Eli Lilly And Company Synthesis of kainic acid
US5438130A (en) 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
US5622965A (en) 1993-03-12 1997-04-22 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
JP3209377B2 (ja) 1993-04-19 2001-09-17 花王株式会社 吸収性物品の製造方法
DK69693D0 (da) 1993-06-14 1993-06-14 Neurosearch As Farven lilla
FR2707880B1 (fr) 1993-06-30 1995-10-06 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
US5434159A (en) 1993-09-14 1995-07-18 Sterling Winthrop Inc. 6,11-cyclyl-1,2,3,4,5,6,11,11a-octahydrobenzo[b]quinolines and compositions and method of use thereof
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US5491241A (en) 1993-10-18 1996-02-13 Eli Lilly And Company Bicyclic intermediates for excitatory amino acid receptor antagonists
US5495042A (en) 1993-11-04 1996-02-27 Cytogen Corporation Non-alkaline purification of aminophosphonic acids
US5459037A (en) 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5500420A (en) * 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US6274330B1 (en) 1993-12-30 2001-08-14 Zymogenetics, Inc. L-AP4 sensitive glutamate receptors
CZ265096A3 (en) 1994-03-14 1997-06-11 Novo Nordisk As Thienoindole derivatives, their use, process of their preparation and pharmaceutical composition containing thereof
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5489717A (en) 1994-07-08 1996-02-06 Warner-Lambert Company Glutamate (NMDA) receptor antagonists
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
US5750566A (en) 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
TR199501070A2 (tr) 1994-08-31 1996-06-21 Lilly Co Eli Dihidro-2,3-benzodiazepin türevinin kristalli bicimi.
FR2726271B1 (fr) 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
US5473077A (en) 1994-11-14 1995-12-05 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
JP3170491B2 (ja) 1999-03-29 2001-05-28 松下電送システム株式会社 画像通信装置及びサーバ装置並びに能力交換方法
JP3762214B2 (ja) 2000-11-28 2006-04-05 株式会社エヌ・ティ・ティ・ドコモ 位置登録制御方法、移動通信網および通信端末

Also Published As

Publication number Publication date
NO991387L (no) 1999-05-27
CA2264043A1 (en) 1998-04-02
JP2002514184A (ja) 2002-05-14
PL332413A1 (en) 1999-09-13
CZ60499A3 (cs) 1999-08-11
HUP0001062A2 (hu) 2001-05-28
EP1005348A1 (en) 2000-06-07
NO991387D0 (no) 1999-03-22
AU4067797A (en) 1998-04-17
TR199901173T2 (xx) 1999-07-21
US6413948B1 (en) 2002-07-02
LV12283A (lv) 1999-06-20
HUP0001062A3 (en) 2001-09-28
NZ334780A (en) 2000-12-22
WO1998013046A1 (en) 1998-04-02
CN1230889A (zh) 1999-10-06
KR20000036227A (ko) 2000-06-26
AU733880B2 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
GB9600426D0 (en) Compositions
PL332118A1 (en) Remineralisable compositions
IL130330A0 (en) Endo-ectoparasiticidal compositions
GB9612067D0 (en) Composition
GB9624874D0 (en) Composition
GB9601398D0 (en) Composition
GB9619074D0 (en) Composition
GB9605247D0 (en) Composition
EP0884044A4 (en) HAIR TREATMENT
GB9624540D0 (en) Compositions
GB9600604D0 (en) Composition
GB9623562D0 (en) Sachet-packaged compositions
GB9620504D0 (en) Compositions
HRP970569A2 (en) Fharmaceutical compositions
GB9602266D0 (en) Composition
GB9610966D0 (en) Composition
GB9620503D0 (en) Compositions
GB9611365D0 (en) Compositions
GB9600545D0 (en) Compositions
GB9604585D0 (en) Composition
GB9616561D0 (en) Compositions
GB9607185D0 (en) Compositions
GB9620445D0 (en) Compositions
GB9603888D0 (en) Compositions
GB9619464D0 (en) Compositions

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)

Owner name: MGI GP, INC.

Free format text: FORMER NAME:GUILFORD PHARMACEUTICALS, INC.